<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166257</url>
  </required_header>
  <id_info>
    <org_study_id>ICN98008</org_study_id>
    <nct_id>NCT00166257</nct_id>
  </id_info>
  <brief_title>PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism</brief_title>
  <official_title>Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Cardiovascular Research, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Cardiovascular Research, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two treatments strategies to prevent further attacks&#xD;
      in patients who have suffered an stroke or occlusion of a major artery with no obvious reason&#xD;
      other than a persistent small opening between the upper heart chambers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients who have suffered a stroke or occlusion of a large artery in another body part of&#xD;
      unknown origin a possible cause is a small opening between the upper heart chambers (patent&#xD;
      foramen ovale, it is called). After birth this opening closes in 75% of the population, while&#xD;
      it persists in 25% of people. It may allow a small blood clot to pass from the veins of the&#xD;
      legs through the heart into the brain or other parts of the body. In order to reduce the risk&#xD;
      for a further attack we have today more therapeutic options to choose from but it is unclear&#xD;
      which strategy have the best outcome. This study is created to compare the effect of two&#xD;
      treatment strategies:&#xD;
&#xD;
        1. Medical treatment The purpose of medical treatment is to dilute the blood to a degree,&#xD;
           that no thrombus formation occurs. Since the opening in the heart persists, treatment is&#xD;
           usually recommended lifelong. And patients treated with coumadin must undergo regular&#xD;
           blood tests to ensure an adequate effect of the drug.&#xD;
&#xD;
        2. Catheter closure of patent foramen ovale An alternative method developed to close the&#xD;
           small opening in the heart utilizes catheters which are introduced in a blood vessel in&#xD;
           the groin and from there advanced to the heart. An umbrella device is then delivered&#xD;
           through the catheter, positioned within the small defect and released. The umbrella is&#xD;
           overgrown with own tissue within weeks to months and closes the small defect for ever.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2000</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death (Fatal stroke, cardiovascular, non-CV),</measure>
    <time_frame>continuosly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>non-fatal cerebrovascular event,</measure>
    <time_frame>continuosly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>peripheral embolism</measure>
    <time_frame>continuosly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New arrhythmias,</measure>
    <time_frame>continuosly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>continuosly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization related to PFO or its treatment</measure>
    <time_frame>continuosly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>device problems</measure>
    <time_frame>continuosly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding complications</measure>
    <time_frame>continuosly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">414</enrollment>
  <condition>Embolism, Paradoxical</condition>
  <condition>Heart Septal Defects, Atrial</condition>
  <arm_group>
    <arm_group_label>Medical antitrhombotic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Device Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous closure of patent foramen ovale</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous closure of patent foramen ovale</intervention_name>
    <description>Percutaneous implantation of an AMPLATZER® PFO Occluder</description>
    <arm_group_label>Device Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical antitrhombotic treatment</intervention_name>
    <description>Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d</description>
    <arm_group_label>Medical antitrhombotic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age below 60 years&#xD;
&#xD;
          -  Ischemic stroke or peripheral thromboembolism, radiologically verified&#xD;
&#xD;
          -  Absence of an identifiable cause of embolism&#xD;
&#xD;
          -  Echocardiographically verified patent foramen ovale&#xD;
&#xD;
          -  Sufficient recovery from index event to allow independent daily activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any identifiable cause for thromboembolic event other than PFO&#xD;
&#xD;
          -  Cardiac diseases: mural thrombus, dilated cardiomyopathy, prosthetic heart valve or&#xD;
             mitral stenosis, endocarditis, atrial fibrillation&#xD;
&#xD;
          -  Vascular system: significant atherosclerosis or dissection of the aorta, collagen&#xD;
             vascular disease, arteritis, vasculitis&#xD;
&#xD;
          -  Pre-existing neurologic disorders or intracranial disease, e.g., multiple sclerosis,&#xD;
             arteriovenous malformations, previous hemorrhage&#xD;
&#xD;
          -  Contraindications for antithrombotic or anticoagulant therapy&#xD;
&#xD;
          -  Patients already on chronic anticoagulant therapy for another disease&#xD;
&#xD;
          -  Previous surgical or percutaneous PFO-closure&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Septicemia or severe infectious disease&#xD;
&#xD;
          -  Severe CNS disease&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Foreseen difficulties with study compliance, especially the long-term follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Meier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Cardiology, University Hospital Insel, Berne, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Prahan</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin II</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Z. Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital / Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>May 26, 2009</last_update_submitted>
  <last_update_submitted_qc>May 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Meier, Bernhard, MD, Professor of Cardiology,</name_title>
    <organization>University of Berne, Switzerland</organization>
  </responsible_party>
  <keyword>Paradoxical embolism, Patent foramen ovale,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
    <mesh_term>Embolism, Paradoxical</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

